Anika Therapeutics Inc., has announced an additional FDA 510 (k) clearance for its Tactoset bone substitute. It can now be used with autologous bone-marrow aspirate.
The release states that a combination of Tactoset, an injectable bone replacement, and autologous bone-marrow aspirate can help improve healing for patients suffering from osteoporosis or cysts.
“Tactoset, a regenerative solutions product, continues to be a key growth driver within our joint preservation and restoration portfolio, as it is positioned
